Clinical Trials Logo

Tobacco Use Disorder clinical trials

View clinical trials related to Tobacco Use Disorder.

Filter by:

NCT ID: NCT03788785 Not yet recruiting - Clinical trials for Tobacco Use Disorder

Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer

Start date: December 2018
Phase: N/A
Study type: Interventional

Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosa of the upper aero-digestive tract. They are the 6th most prevalent type of cancer worldwide. The risk related to tobacco is particularly high in the case of HNSCC, as the prevalence of heavy smoking for long periods is high in this population. The investigators' aim is to compare two models: one is a specific model of tobacco cessation intervention designed for health care teams treating patients with HNSCC; the other is the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation. The investigators will evaluate the efficacy of this intervention 12 months after randomization. This intervention will be implemented into otolaryngology (ENT) care by training ENT nurses with a specific program for tobacco cessation delivered to patients diagnosed with HNSCC.

NCT ID: NCT03764969 Not yet recruiting - Clinical trials for Tobacco Use Disorder

Modification of Goal-directed and Habitual Behavior in Addiction

Start date: July 2019
Phase: N/A
Study type: Interventional

This study aims to examine the modification of the hypothesized imbalance between goal-directed and habitual behavior and its neural correlates in smokers. Two interventions will be used as add-on trainings to a smoking cessation program.

NCT ID: NCT03744559 Not yet recruiting - Clinical trials for Nicotine Use Disorder

Behavioral Memory Modulation in Nicotine Addiction

Start date: January 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to see if a behavioral intervention known as retrieval-extinction training (RET) might affect craving in response to nicotine cues (e.g., pictures, videos and objects) and smoking behavior in men and women who smoke cigarettes.

NCT ID: NCT03720899 Not yet recruiting - Smoking Cessation Clinical Trials

Comparing NicoBloc to Nicotine Lozenges

Start date: January 31, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

To examine the feasibility, acceptability, and preliminary impact of using NicoBloc compared to nicotine lozenges

NCT ID: NCT03719391 Completed - Nicotine Dependence Clinical Trials

United States Pre-Market Tobacco Application Pharmacokinetics

Start date: October 19, 2018
Phase: N/A
Study type: Interventional

A Randomized, Open-Label, Cross-Over Study to Assess Nicotine Uptake and Subjective Measures with Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) Compared to Usual Brand Combustible Cigarettes, a Comparator E-Cigarette, and Nicotine Gum in Healthy Adult Smokers

NCT ID: NCT03713424 Not yet recruiting - Clinical trials for Tobacco Use Disorder

The Effects of Clavulanic Acid on Tobacco Use Disorder

Start date: January 2019
Phase: Phase 2
Study type: Interventional

This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.

NCT ID: NCT03712098 Recruiting - Smoking Cessation Clinical Trials

Daily Liraglutide for Nicotine Dependence

Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain. In this double-blind, placebo-controlled, parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be randomized to 32 weeks of liraglutide or placebo and undergo 8 sessions of smoking cessation behavioral counseling. Outcomes are smoking abstinence and weight change.

NCT ID: NCT03707600 Not yet recruiting - Nicotine Dependence Clinical Trials

State and Trait Mediated Response to TMS in Substance Use Disorder

Start date: January 18, 2019
Phase: Early Phase 1
Study type: Interventional

OBJECTIVES: The current protocol seeks to develop brain-based intermediate phenotypes of response to transcranial magnetic stimulation (TMS) in chronic substance use disorder (SUD). To date the field has relied on subjective reports, behavioral performance, and long-term clinical outcomes as primary measures of TMS efficacy. While certainly ecologically valid, these observable behaviors lack the sensitivity necessary to fully quantify the effects (or lack thereof) across both individual participants and TMS intervention protocols. This proposed within-subjects design seeks to leverage differences in metaplasticity that is, the context in which stimulation occurs-by studying the response to stimulation in both sated and abstinent states. It is predicted these state manipulations will potentiate response to TMS. When a disruptive allostatic load like chronic nicotine exposure or acute abstinence is placed on the brain, the underlying network becomes less stable and thus more susceptible to TMS intervention. For SUD in general and tobacco use disorder (TUD) in particular, this state dependence of TMS response is a potentially valuable tool to improve a given intervention s clinical efficacy. STUDY POPULATION: Physically and psychiatrically healthy smokers will be recruited. A comparison group of non-smokers will be concurrently enrolled. We estimate we will require n=51/group of completers to have sufficient power to develop the intermediate phenotypes of TMS. DESIGN: The protocol is a two group, between/within subject, fully counterbalanced design. The between-subjects factor is GROUP (smoker/non-smoker) and the within-subjects factor for each GROUP is TMS CONDITION (active/sham). Additionally, and for the smoker group, nicotine STATE (sated/abstinent) is a nested within-subjects factor. Each group will receive single sessions of active and sham intermittent theta burst stimulation to left dorsal lateral prefrontal cortex, followed immediately by an MRI scan to characterize the acute neurobiological response to stimulation. Smokers will repeat these procedures both during smoking satiety and following an ~48-hour period nicotine abstinence. OUTCOMES PARAMETERS: In addition to subjective and behavioral task performance changes associated with TMS intervention, changes in MRI BOLD signal will be used to characterize the neurobiological response to TMS intervention across groups and states. Taken together, the development of brain-based markers of TMS response may thus improve both our mechanistic understanding of the causal dysfunctions of TUD as well as the potential efficacy of these interventions longer term to address the relevant clinical characteristics of the disease and ultimately improve treatment outcomes.

NCT ID: NCT03700112 Enrolling by invitation - Nicotine Dependence Clinical Trials

Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.

Start date: December 7, 2018
Phase: N/A
Study type: Interventional

A Randomized Study Comparing Nicotine Pharmacokinetics of Seven Electronic Cigarette Products and One Traditional Cigarette Across Two Delivery (10 puff and ad- libitum) Conditions, in Healthy Adult Smokers

NCT ID: NCT03694327 Recruiting - Smoking Cessation Clinical Trials

Innovative Digital Therapeutic for Smoking Cessation

Start date: October 24, 2018
Phase: N/A
Study type: Interventional

This study is comparing the efficacy of two smoking cessation apps.